Renvela generics — when can they launch?
Renvela (SEVELAMER CARBONATE) · Sanofi · 2 active US patents · 0 expired
Where Renvela sits in the generic timeline
Mid-term cliff: earliest active US patent for Renvela expires in 2030 (~5 years). Generic developers typically begin ANDA bioequivalence studies 3-4 years ahead of this date. Paragraph IV filings + Hatch-Waxman 30-month stays may shift the effective entry by another 18-36 months.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Formulation — 2 patents
Sample patent estate
Showing 2 of 2 active US patents. View full estate on the Renvela drug page →
-
This patent protects a powder formulation of an aliphatic amine polymer or a pharmaceutically acceptable salt thereof, packaged in a container such as a sachet.USPTO title: Sachet formulation for amine polymers
-
This patent protects a powder formulation of an aliphatic amine polymer or a pharmaceutically acceptable salt thereof, packaged in a container such as a sachet.USPTO title: Sachet formulation for amine polymers
Sources
- FDA Orange Book — patents listed against Renvela (NDA filed 2007)
- Renvela drug profile — full patent estate, indications, clinical trials, pricing
- Sanofi patent portfolio
- Patent cliff 2030 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Renvela — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →